Chengdu Kanghua Biological Products Co., Ltd. (SHE:300841)
China · Delayed Price · Currency is CNY 60.89
+0.90 (1.50%)
Apr 21, 2026, 3:04 PM CST
SHE:300841 Revenue
Chengdu Kanghua Biological Products had revenue of 172.45M CNY in the quarter ending March 31, 2026, with 25.02% growth. This brings the company's revenue in the last twelve months to 1.20B, down -4.68% year-over-year. In the year 2025, Chengdu Kanghua Biological Products had annual revenue of 1.17B, down -18.64%.
Revenue (ttm)
1.20B
Revenue Growth
-4.68%
P/S Ratio
6.60
Revenue / Employee
1.93M
Employees
620
Market Cap
7.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.17B | -266.88M | -18.64% |
| Dec 31, 2024 | 1.43B | -145.52M | -9.23% |
| Dec 31, 2023 | 1.58B | 130.67M | 9.03% |
| Jan 1, 2023 | 1.45B | 154.28M | 11.94% |
| Jan 1, 2022 | 1.29B | 253.81M | 24.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.17B |
| Anhui Huaheng Biotechnology | 2.86B |
| Xiangxue Pharmaceutical | 1.47B |
| Nanjing Vazyme Biotech | 1.38B |
| Wuhan Keqian Biology Co.,Ltd | 949.74M |
| Acrobiosystems | 794.52M |
| GemPharmatech | 793.25M |
| Daan Gene | 765.48M |